PA-BENTLEY-SYSTEMS
1.12.2021 22:03:10 CET | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the Year in Infrastructure 2021 Founders’ Honorees. During the 2021 Year in Infrastructure and Going Digital Awards virtual event today, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201006051/en/
Bentley Systems founders Keith and Greg Bentley, and Bentley’s Director of ES(D)G Rodrigo Fernandes, reviewed the compelling credentials of 18 Honorees selected from 230 organizations who submitted nominations for the company’s annual Going Digital Awards in Infrastructure program. Chief Acceleration Officer Santanu Das recognized three Honoree organizations respectively for Infrastructure IoT , iTwin Enterprise , and iTwin Entrepreneur . Nick Smallwood, CEO, on behalf of the U.K.’s Infrastructure and Projects Authority, was honored for ES(D)G Advocacy .
The Year in Infrastructure 2021 Founders’ Honorees are:
ES(D)G Honoree for Affordable and Clean Energy
Fujian Yongfu Power Engineering Co., Ltd.
Fujian Changle Zone C Offshore Wind Farm
Changle/Fuzhou, Fujian, China
ES(D)G Honoree for Climate Action
Evides NV
Pumping Energy Optimization and CO2 Reduction Evides Case Study
Rotterdam, Netherlands
ES(D)G Honoree for Sustainable Cities and Communities
GenMap
Tree Modeling and Feature Extraction Using Mobile Mapping
Mendoza, Argentina
For 4D Design Review
PT MRT Jakarta (Perseroda)
MRT Jakarta Phase II
Jakarta, Indonesia
For 4D Digital Twins Advancement
WSB
TH 169: Redefine Elk River
Elk River, Minnesota, United States
For As-Operated Digital Twin
CNOOC Energy Development Design and R&D Center
Digital Twin Project of the FPSO Offshore Oil Gathering and Transportation Platform
South China Sea, Guangdong, China
For Collaborative Success
Wood
Wood Bentley Digital Community Collaborative Portal
United Kingdom
For Comprehensive Collaboration
CES_SDC Pte Ltd & AECOM Singapore Pte Ltd
Tuas Water Reclamation Plant - Contract C4A - BioSolids & Digesters
Singapore
For Comprehensive Project Digital Twin
China Railway First Survey and Design Institute Group Co., Ltd.
Application of BIM Technology in the Design of Xi’an-Shiyan High-Speed Railway
Xi’an, Lantian, Shangluo, Shanyang, and Shiyan; Shaanxi and Hubei; China
For Digital Adaptation
AFRY & Tyréns Consortium
East Link
Stockholm, Sweden
For Digital Integrator
Mott MacDonald and National Grid
London Power Tunnels 2
London, United Kingdom
For Digital Twins R&D
Shanghai Investigation, Design & Research Institute Co., Ltd.
The Application of Digital Twin Technology in the Full Lifecycle of Offshore Wind Power Projects
Beijing, China
For ES(D)G Advocacy
Nick Smallwood (on behalf of Infrastructure and Projects Authority)
Infrastructure and Projects Authority
United Kingdom
For Global Future-proofing
Brigantium Engineering
ITER: In-Pit Activities for Tokamak Assembly
St. Paul-les-Durance, Bouches-du-Rhone, France
For Going Digital in Education
Center for Industrial Technological Studies and Services No. 33
CETIS 33 BIM Workshop
Mexico City, Mexico
For Infrastructure IoT
GZA GeoEnvironmental
United States
For iTwin Enterprise
Consilience Analytics
United States
For iTwin Entrepreneur
SewerAI
United States
For National Digital Twin
Singapore Land Authority
Advancing Singapore National 3D Reality Mapping for a Changing World
Singapore
For Pandemic-proof Execution
PT Hutama Karya (Persero)
Modification of Surabaya - Gresik Toll Road Interchange
Surabaya, East Java, Indonesia
For Project Delivery Visibility
Zachry Industrial, Inc., a Zachry Group Company
Golden Pass LNG Export Project
Sabine Pass, Texas, United States
For Virtuoso Invention
NP Singh
GMW Pvt. Ltd.
India
To view the project descriptions and access the images, visit the Founders’ Honorees webpage. Detailed descriptions of all nominated projects will be published in the print and digital versions of Bentley’s 2021 Infrastructure Yearbook in early 2022. To review the past editions of this publication, access Bentley’s Infrastructure Yearbooks .
Watch the executive sessions and the Going Digital Awards finalists’ presentations from the 2021 Year in Infrastructure and Going Digital Awards virtual event on-demand here.
# #
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom